These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 14747047

  • 1. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ, Radiation Therapy Oncology Group P-0014.
    Urology; 2003 Dec 29; 62 Suppl 1():95-101. PubMed ID: 14747047
    [Abstract] [Full Text] [Related]

  • 2. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR, Carducci MA, Eastern Cooperative Oncology Group E1899.
    Urology; 2003 Dec 29; 62 Suppl 1():141-6. PubMed ID: 14747052
    [Abstract] [Full Text] [Related]

  • 3. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002 Dec 29; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

  • 4. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF, Lee WR.
    Arch Esp Urol; 2011 Oct 29; 64(8):858-64. PubMed ID: 22052767
    [Abstract] [Full Text] [Related]

  • 5. Innovations in the systemic therapy of prostate cancer.
    Shepard DR, Raghavan D.
    Nat Rev Clin Oncol; 2010 Jan 29; 7(1):13-21. PubMed ID: 19997075
    [Abstract] [Full Text] [Related]

  • 6. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ, Small EJ.
    Urology; 2003 Dec 29; 62 Suppl 1():87-94. PubMed ID: 14747046
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul 29; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ.
    Nat Rev Clin Oncol; 2013 Mar 29; 10(3):126-8. PubMed ID: 23381000
    [No Abstract] [Full Text] [Related]

  • 12. Neoadjuvant androgen suppression and external beam radiation therapy.
    Zietman AL, Smith CT.
    Front Radiat Ther Oncol; 2002 Mar 29; 36():87-98. PubMed ID: 11842759
    [No Abstract] [Full Text] [Related]

  • 13. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Mar 29; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 14. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.
    Urology; 2003 Jul 29; 62(1):99-104. PubMed ID: 12837431
    [Abstract] [Full Text] [Related]

  • 15. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H.
    Int J Radiat Oncol Biol Phys; 2015 Oct 01; 93(2):294-302. PubMed ID: 26209502
    [Abstract] [Full Text] [Related]

  • 16. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 01; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.